Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $7.00 → $10.00 | Market Perform → Outperform | SVB Securities |
| 3/2/2022 | $30.00 → $15.00 | Buy | Benchmark |
| 2/28/2022 | $23.00 → $11.00 | Market Perform | SVB Leerink |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Robert W. Baird |
| 2/1/2022 | $24.00 → $11.00 | Outperform → Neutral | Baird |
| 12/2/2021 | $13.00 | Hold | Jefferies |
| 11/8/2021 | $70.00 → $23.00 | Outperform | RBC Capital |
| 11/8/2021 | $40.00 → $23.00 | Market Perform | SVB Leerink |
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
$10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti
Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million
MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe
First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu
SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously
SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)
Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre
MOORESTOWN, N.J., Nov. 1, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of April D. Gill as Chief Commercial Officer. Ms. Gill has more than 20 years of experience in healthcare with a proven track record exceeding client satisfaction, sales, and profitability goals. In this newly created role, Ms. Gill will oversee development and execution of TRHC's commercialization with broad responsibility for strategy, product, marketing, communication
Drs. Calvin H. Knowlton and Orsula V. Knowlton to retire from the Company Co-President Brian Adams Named Interim CEO Director Michael Purcell Named Independent Board Chairman MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that co-founders Dr. Calvin H. Knowlton, BScPharm, MDiv, PhD, ScD (hon), Chief Executive Officer and Board Chairman, and Dr. Orsula V. Knowlton, PharmD, MBA, Co-President and Chief Marketing and New Business Development Officer, will retire from TRHC and step down as members of the Board of Directors, effective immediately. Dir
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P 500, also rose, gaining, 0.65% to 4,507.13. Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Financials shares jumped by 1.4% on Monday. In trading on Monday, information technology shares fell 0.1%. Top Headline Henry Schein Inc (NASDAQ:HSIC) reported better-than-expected second-quarter earnings. Henry Schein posted quarterly sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2%
Nautic Partners agreed to acquire Tabula Rasa HealthCare Inc (NASDAQ:TRHC) for $10.50 in cash per share and combine with ExactCare Pharmacy, a portfolio company of Nautic. The all-cash transaction values Tabula Rasa at approximately $570 million including net debt of approximately $262 million on an enterprise value basis. Following the closing of the transaction, John Figueroa, ExactCare's current Executive Chairman, will assume the role of Chairman and CEO of the combined company. The transaction is expected to close during Q4 of 2023. The deal expands the reach of Tabula Rasa's MedWise technology platform to multiple provider and payer markets. Tabula Rasa HealthCare reported Q2 adj
Gainers Vistagen Therapeutics (NASDAQ:VTGN) shares rose 871.4% to $16.32 during Monday's regular session. Trading volume for this security as of 13:30 EST is 40.9 million, which is 18764.9% of its average full-day volume over the last 100 days. The company's market cap stands at $130.3 million. Nektar Therapeutics (NASDAQ:NKTR) shares increased by 89.89% to $1.01. The current volume of 138.1 million shares is 4109.5% of Nektar Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $191.3 million. Tabula Rasa HealthCare (NASDAQ:TRHC) stock increased by 30.84% to $10.24. Trading volume for Tabula Rasa Hea